Suggestions
Elli Papaemmanuil
Associate Professor Computational Oncology Service MSKCC, Isabl Co-founder & CEO
Elli Papaemmanuil is a distinguished scientist and entrepreneur who co-founded and currently serves as the CEO of Isabl, a company focused on transforming cancer diagnosis and treatment through genomic medicine.13
Academic and Professional Background
Elli Papaemmanuil holds a PhD in Human Population Genetics from the University of London, which she completed between 2004 and 2008.1 Her educational journey began with a Bachelor of Science in Human Molecular Genetics from the University of Glasgow from 2000 to 2004.1
Throughout her career, Dr. Papaemmanuil has held several notable positions:
- Associate Professor of Computational Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC) since 201525
- Junior Team Leader at the University of Cambridge from 2016 to 20201
- Senior Postdoctoral Research Fellow at Wellcome Trust Sanger Institute in 20101
- Postdoctoral Researcher at The Institute of Cancer Research in 20041
Research and Expertise
Dr. Papaemmanuil is a molecular geneticist with expertise in:
- Applying AI to precision medicine3
- Systematic interrogations of clinical trial cohorts in leukemia and cancer2
- Exploring how genetic and clonal architecture in patients' leukemias and tumors influence clinical outcomes2
Her research has been widely recognized, with publications in prestigious journals such as NEJM, Nature Genetics, and Nature Medicine. She has garnered over 43,000 citations and boasts an h-index of 70.3
Entrepreneurial Ventures
In 2020, Elli Papaemmanuil co-founded Isabl, where she serves as the CEO and Scientific Co-founder.13 Isabl aims to unlock the full potential of genomic medicine in cancer care by developing technology to profile tumor biopsies using whole genome and transcriptome sequencing within clinically relevant timeframes.36
Achievements and Recognition
Dr. Papaemmanuil's accomplishments include:
- Josie Robertson Investigator (2015-2020)2
- European Hematology Association Young Investigator Award2
- Cancer Research UK Career Development Award2
Her LinkedIn profile can be found under the username elli-papaemmanuil-0b8444b0.4
Highlights
Are physicians ready to adopt clinical decision support tools to interpret molecular profiling data?
In 2 months since its publication the IPSS-M Model (International Prognostic Scoring System Molecular) developed in our lab to guide risk stratification and treatment decisions for patients with MDS has been accessed by 2,291 unique users, from 65 countries performing in total 18,210 patient queries.
Profiling cancer patient genomes at scale is no longer a challenge. We now need to solve the interpretation challenge and help oncologists deliver end-to-end patient tailored care, not just inform treatment decisions and targeted therapies, but identify who is at risk of developing cancer, mitigate treatment related toxicities, guide surveillance strategies for relapse and long term co-morbidities.
Some background info:
The IPSS-M was published at NEJM Evidence https://bit.ly/3aNEU64. A result of an international collaboration, involving >24 centers from 13 countries. In the absence of targeted therapies, risk stratification guides treatment decisions for MDS patients. The IPSS-M was the first model to consider information from mutations in 31 genes and led to significant improvement in risk stratification (1 in 2 MDS patients changed risk score).
To facilitate adoption, we launched a web based clinical decision support tool https://lnkd.in/eisXxP9s
You can read more about it here: https://lnkd.in/eATprc4C
We thank all the collaborators and patient participants.
#precisionmedicine #precisiononcology #mds
How can DNA testing further our abilities to personally tailor care for our cancer patients, not just for their cancer but also for their long term risks such as the development of therapy related leukemia?
Increasingly cancer patients receive genetic testing of their tumor and in some cases a blood sample to act as the "reference" DNA. Tumor DNA testing enables doctors identify the best therapies for cancer patients.
In our study, published today at Nature Genetics, we studied mutations that occur in the blood as predictive biomarkers that identify which cancer patients may subsequently develop therapy related leukemia, years before disease onset. We characterize how cancer therapy may further increase that risk for a subset of high risk patients. Last, we model how risk adapted treatment decisions can mitigate the long term risk of therapy related leukemia. End to end precision medicine.
As we improve our primary cancer care, and with 18 million cancer survivors expected by 2022, preventing the onset of therapy related leukemia, which is one of the most lethal cancers is no small feat.
Very excited to be part of this team effort at Memorial Sloan Kettering. Read more about it here:
